PharmaSGP exceeds the EUR 100 million revenues mark in 2023 and plans
further profitable growth in 2024

EQS-News: PharmaSGP Holding SE / Key word(s): Preliminary Results/Forecast
PharmaSGP exceeds the EUR 100 million revenues mark in 2023 and plans further
profitable growth in 2024

16.04.2024 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PharmaSGP exceeds the EUR 100 million revenues mark in 2023 and plans further
profitable growth in 2024

Gräfelfing, April 16, 2024 - German OTC pharmaceutical company PharmaSGP
Holding SE continued the successful development of previous years in the
2023 financial year and exceeded the EUR 100 million revenues mark for the
first time in the company's history at EUR 101.1 million based on preliminary,
unaudited figures. The increase in revenues of 17.8% compared to the
prior-year period (EUR 85.8 million) is based on the strong organic growth
achieved by PharmaSGP through the consequent execution of its well-proven
platform strategy. Adjusted earnings before interest, taxes, depreciation
and amortization (adjusted EBITDA) amounted to EUR 34.1 million in the 2023
financial year, an increase of 20.8% compared to the previous year (EUR 28.2
million). As a result, the adjusted EBITDA margin rose to 33.7% (previous
year: 32.9%). Both revenues and adjusted EBITDA are slightly above the 2023
forecast.

CEO Natalie Weigand comments: "With great satisfaction we look back on a
successful financial year 2023, in which we achieved a strong performance in
terms of both revenues and profitability. The fact that we achieved our
growth exclusively organically demonstrates the sustainable strength of our
platform strategy and the efficiency of our marketing activities."

CFO Michael Rudolf adds: "We reached a milestone last year by exceeding the
EUR 100 million revenues mark for the first time. The fact that we slightly
exceeded our forecast in terms of revenues and adjusted EBITDA in an overall
challenging market environment impressively underlines the resilience of our
growth strategy. This will also enable us to achieve further growth in the
future and to optimally exploit the potential of our business model."

For the current 2024 financial year, the Management Board of PharmaSGP
expects the success story to continue with revenues in a range between EUR
107.0 million and EUR 112.0 million. The Management Board is also forecasting
a further increase in adjusted EBITDA with earnings of between EUR 35.0
million and EUR 38.0 million. This corresponds to an adjusted EBITDA margin of
32.7% to 33.9%.

PharmaSGP will publish its full annual report for 2023 on 29 April, 2024.

OVERVIEW OF PRELIMINARY YEAR-ON-YEAR FIGURES

    Consolidated figures (in EUR million)           2023         2022       
    Revenues                                     101.1         85.8  +17.8%
    Adjusted EBITDA                               34.1         28.2  +20.8%
    Unadjusted EBITDA                             34.0         26.9  +26.3%
    Adjusted EBITDA margin                       33.7%        32.9%
    Unadjusted EBITDA margin                     33.6%        31.4%

    Revenues by region (in EUR million)             2023         2022       
    Germany                                       73.4         61.3  +19.6%
    Italy                                         13.6         10.5  +28.8%
    Austria                                       10.5          9.8   +7.8%
    Other European countries                       3.7          4.2  -13.0%

    Revenues share by region                      2023         2022
    Germany                                      72.6%        71.5%
    Italy                                        13.4%        12.3%
    Austria                                      10.4%        11.4%
    Other European countries                      3.6%         4.8%

    Revenues by product category (in EUR million)         2023   2022       
    Health Brands                                 97.5         82.5  +18.2%
    Beauty Brands                                  3.5          3.3   +6.0%

CONTACT

cometis AG
Claudius Krause
Phone: +49-611-20585528
Email: ir@pharmasgp.com

ABOUT PHARMASGP HOLDING SE

PharmaSGP is a leading consumer health company with a diversified portfolio
of over-the-counter (OTC) pharmaceuticals and other healthcare products that
are marketed with a focus on the pharmacy distribution channel. These
products are mostly based on natural active pharmaceutical ingredients with
documented efficacy and few known side effects.

The Company's core brands cover chronic indications, including rheumatic
pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is
the market leader for systemic chemical-free pain remedies with its brand
families RubaXX® for rheumatic pain and Restaxil® for neuralgic pain.
Furthermore, PharmaSGP also offers leading products against sexual weakness
and vertigo symptoms. Since introducing the first product from the current
product portfolio in 2012, PharmaSGP has successfully established its
business model in other European countries, including Austria, Italy,
Belgium, Spain and France. In September 2021, the product portfolio was
expanded by the brands Baldriparan®, Formigran®, Spalt® and Kamol®, thus
also strengthening or developing the indications pain and sleep disorder.
The sales territory was expanded to include Switzerland and Eastern Europe.
In 2023, PharmaSGP generated revenues of EUR 101.1 million at an adjusted
EBITDA margin of 33.7% based on preliminary, unaudited figures.

In order to further expand its competitive position, PharmaSGP plans to
increase the number of indications covered by PharmaSGP's product offering,
increase PharmaSGP's European footprint, and accelerate its growth strategy
especially by capitalizing on selected M&A opportunities.


---------------------------------------------------------------------------

16.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        PharmaSGP Holding SE
                   Lochhamer Schlag 1
                   82166 Gräfelfing
                   Germany
   E-mail:         ir@pharmasgp.com
   Internet:       https://pharmasgp.com
   ISIN:           DE000A2P4LJ5
   WKN:            A2P4LJ
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Munich, Tradegate Exchange
   EQS News ID:    1880509

End of News EQS News Service
---------------------------------------------------------------------------

1880509 16.04.2024 CET/CEST